MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options

Rhea-AI Filing Summary

MIRA PHARMACEUTICALS, INC. reported that director Shekhat Denil Nanji received a grant of stock options to buy 50,000 shares of common stock at an exercise price of $0.94 per share on June 12, 2026. The options were granted under the company’s 2022 Omnibus Incentive Plan as compensation, not as an open‑market purchase.

According to the grant terms, 50% of the options vest six months after the grant date and the remaining 50% vest one year after the grant date. The options expire on June 12, 2036 if not exercised. After this award, Nanji holds 50,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shekhat Denil Nanji

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

Key Figures

Option grant size: 50,000 options Exercise price: $0.94 per share Post-grant derivative holdings: 50,000 options +3 more

6 metrics

Option grant size 50,000 options Stock options granted on June 12, 2026

Exercise price $0.94 per share Exercise price of granted stock options

Post-grant derivative holdings 50,000 options Total options held following the transaction

Option term Expires June 12, 2036 Expiration date of the granted options

Initial vesting 50% at six months First tranche vests six months after grant date

Final vesting 50% at one year Second tranche vests one year after grant date

Key Terms

Stock Options, exercise price, 2022 Omnibus Incentive Plan, vesting

4 terms

Stock Options financial

"Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"at an exercise price of $0.94 each"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2022 Omnibus Incentive Plan financial

"pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated"

vesting financial

"50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 05:00 PM Accepted by SEC EDGAR 06/15/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shekhat Denil Nanji

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.94(1)	06/12/2026		A		50,000		(2)	06/12/2036	Common Stock	50,000	$0	50,000(3)	D

Explanation of Responses:

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

2. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

3. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

	/s/ Denil Shekhat	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MIRA (MIRA) report for Shekhat Denil Nanji?

MIRA reported that director Shekhat Denil Nanji received a grant of 50,000 stock options on June 12, 2026. These options are compensation awards, not open-market purchases or sales, and give the right to buy common shares at a fixed exercise price.

How many stock options were granted to the MIRA (MIRA) director and at what price?

The director received 50,000 stock options with an exercise price of $0.94 per share. This means Nanji can purchase up to 50,000 MIRA common shares at $0.94, regardless of the future market price, once the options vest and before expiration.

What is the vesting schedule for the 50,000 MIRA (MIRA) stock options?

The 50,000 stock options vest in two equal tranches. Half of the options vest six months after the June 12, 2026 grant date, and the remaining half vest one year after the grant date, assuming continued service under the company’s incentive plan.

When do the newly granted MIRA (MIRA) stock options expire?

The granted stock options expire on June 12, 2036, giving a 10-year term from the grant date. Nanji must exercise any vested options before that expiration date or they will lapse and no longer be exercisable for MIRA common shares.

Are the MIRA (MIRA) director’s 50,000 options an open-market share purchase?

No. The 50,000 options are a grant under MIRA’s 2022 Omnibus Incentive Plan. They represent a compensation award rather than an open-market purchase, and become exercisable only as they vest at the specified future dates.